Exp Ther Med 15:50775083 Mieczkowska A, Millar P, Chappard D, Gault VA, Mabilleau G (2020) Dapagliflozin and liraglutide therapies rapidly enhanced bone material properties and matrix biomechanics at bone formation site in a type 2 diabetic mouse model
Sterne JAC, Savovi J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H, Corbett MS, Eldridge SM, Emberson JR, Hernn MA, Hopewell S, Hrbjartsson A, Junqueira DR, Jni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT
Its main function is to target the skins sebaceous glands and decrease excess oil, making it very effective for acne with a hormonal component
The pharmaceutical industry's evolution in obesity therapeutics has progressed from single-target approaches (pure GLP-1 agonists like semaglutide) to dual agonists (GLP-1/GIP like tirzepatide), and now to triple agonists like retatrutide that attempt to orchestrate an even more comprehensive metabolic remodeling by simultaneously modulating multiple complementary pathways
In Australia, semaglutide as Wegovy and tirzepatide as Mounjaro are registered for weight management